US 12,297,280 B2
Monoclonal antibodies against human interleukin-4 receptor alpha, encoding nucleic acids thereof and method of use thereof to treat IL-4 or IL-4/IL-13-mediated diseases
Jiwan Qiu, Jiangsu (CN); Wei Chen, Jiangsu (CN); Zhihua Qiu, Jiangsu (CN); Huaiyao Qiao, Jiangsu (CN); and Yiliang Wu, Jiangsu (CN)
Assigned to QYUNS THERAPEUTICS CO., LTD., Jiangsu (CN)
Appl. No. 17/418,571
Filed by QYUNS THERAPEUTICS CO., LTD., Jiangsu (CN)
PCT Filed Dec. 25, 2019, PCT No. PCT/CN2019/128156
§ 371(c)(1), (2) Date Jun. 25, 2021,
PCT Pub. No. WO2020/135471, PCT Pub. Date Jul. 2, 2020.
Claims priority of application No. 201811592427.X (CN), filed on Dec. 25, 2018.
Prior Publication US 2022/0073631 A1, Mar. 10, 2022
Int. Cl. C07K 16/28 (2006.01)
CPC C07K 16/2866 (2013.01) [C07K 2317/24 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)] 14 Claims
 
1. An antibody or fragment thereof that is either:
a) a recombinant antibody or fragment thereof against human IL-4Rα comprising three heavy chain complementarily regions (CDR-H1, CDR-H2 and CDR-H3) and three light chain complementary determining regions (CDR-L1, CDR-L2 and CDR-L3),
wherein the amino acid sequence of CDR-H1 is set forth in SEQ ID NO: 1, the amino acid sequence of CDR-H2 is set forth in SEQ ID NO: 2, the amino acid sequence of CDR-H3 is set forth in SEQ ID NO: 3, the amino acid sequence of CDR-L1 is set forth in SEQ ID NO: 4, the amino acid sequence of CDR-L2 is set forth in SEQ ID NO: 5, and the amino acid sequence of CDR-L3 is set forth in SEQ ID NO: 6, or
b) a recombinant antibody or fragment thereof against human IL-4Rα comprising a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 12 and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 13; or
c) an isolated monoclonal antibody against human IL-4Rα comprising three heavy chain complementarily regions (CDR-H1, CDR-H2 and CDR-H3) and three light chain complementary determining regions (CDR-L1, CDR-L2 and CDR-L3),
wherein the amino acid sequence of CDR-H1 is set forth in SEQ ID NO: 1, the amino acid sequence of CDR-H2 is set forth in SEQ ID NO: 2, the amino acid sequence of CDR-H3 is set forth in SEQ ID NO: 3, the amino acid sequence of CDR-L1 is set forth in SEQ ID NO: 4, the amino acid sequence of CDR-L2 is set forth in SEQ ID NO: 5, and the amino acid sequence of CDR-L3 is set forth in SEQ ID NO: 6, or
d) an isolated monoclonal antibody against human IL-4Rα comprising a heavy chain variable region and a light chain variable region, wherein: the amino acid sequence of the heavy chain variable region is set forth in SEQ ID NO: 12 and the amino acid sequence of the light chain variable region is set forth in SEQ ID NO: 13.